First-Line Herceptin® Monotherapy in Metastatic Breast Cancer
@article{Vogel2001FirstLineHM, title={First-Line Herceptin® Monotherapy in Metastatic Breast Cancer}, author={C. Vogel and M. Cobleigh and D. Tripathy and J. Gutheil and L. N. Harris and L. Fehrenbacher and D. Slamon and M. Murphy and W. Novotny and M. Burchmore and S. Shak and S. Stewart}, journal={Oncology}, year={2001}, volume={61}, pages={37 - 42} }
The pivotal phase II and III Herceptin® trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in combination with chemotherapy, respectively. In the current trial, 114 patients were randomized to one of two dose groups of first-line Herceptin monotherapy: standard dose of 4 mg/ kg initial dose followed by 2 mg/kg intravenous (i.v.) weekly; or high dose of 8 mg/kg initial dose followed by 4 mg/kg i.v. weekly. The regimen was generally well… CONTINUE READING
Paper Mentions
News Article
201 Citations
Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic Breast Cancer: A single institutional experience
- Medicine
- Breast cancer
- 2006
- 8
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
- Medicine
- Clinical cancer research : an official journal of the American Association for Cancer Research
- 2003
- 92
- PDF
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
- Medicine
- 2011
- 6
A case of metastatic Breast Cancer with HER2 gene amplification that responded completely to single agent trastuzumab
- Medicine
- Breast cancer
- 2006
- 6
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2010
- 100
Prolonged Survival of Patients Receiving Trastuzumab beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)
- Medicine
- Oncology Research and Treatment
- 2005
- 69
- PDF
Trastuzumab-containing regimens for metastatic breast cancer.
- Medicine
- The Cochrane database of systematic reviews
- 2014
- 139
- PDF
Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation
- Medicine
- Breast Care
- 2006
- 2
- PDF
Platinum-based chemotherapy in metastatic breast cancer: current status.
- Medicine
- Cancer treatment reviews
- 2004
- 171
Trastuzumab containing regimens for early breast cancer.
- Medicine
- The Cochrane database of systematic reviews
- 2012
- 437
References
SHOWING 1-10 OF 23 REFERENCES
Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials
- Medicine
- Oncology
- 2001
- 173
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1998
- 1,051
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
- Medicine
- Oncology
- 2001
- 139
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1999
- 2,722
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1996
- 1,375
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
- Medicine
- Seminars in oncology
- 1999
- 306
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
- Medicine
- The New England journal of medicine
- 2001
- 9,112
- PDF
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
- Biology, Medicine
- Oncogene
- 1999
- 683
- PDF
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
- Biology, Medicine
- Oncogene
- 1997
- 352
- PDF